Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
•
Medical Oncology
•
General Internal Medicine
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
Related Questions
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
Would you change treatment approach for rectal cancer with an associated intussusception?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
Do you prescribe respiratory muscle training (RMT) devices to patients with dysphagia?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
